[go: up one dir, main page]

NO20083605L - Stable oral pharmaceutical composition containing thyroid hormone receptor agonists - Google Patents

Stable oral pharmaceutical composition containing thyroid hormone receptor agonists

Info

Publication number
NO20083605L
NO20083605L NO20083605A NO20083605A NO20083605L NO 20083605 L NO20083605 L NO 20083605L NO 20083605 A NO20083605 A NO 20083605A NO 20083605 A NO20083605 A NO 20083605A NO 20083605 L NO20083605 L NO 20083605L
Authority
NO
Norway
Prior art keywords
hormone receptor
thyroid hormone
pharmaceutical composition
composition containing
receptor agonists
Prior art date
Application number
NO20083605A
Other languages
English (en)
Inventor
Neeraj Garg
Venkatramana M Rao
Rajesh Gandhi
William Washburn
Konrad Koehler
Johan Malm
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of NO20083605L publication Critical patent/NO20083605L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Det beskrives preparater der visse tyroidhormonreseptorbindingsforbindelser er formulert sammen med enten et enterisk belegg, en antioksidant eller både et enterisk belegg og en antioksidant. Slike formuleringer virker for å hindre dannelse av uønskede reaksjonsprodukter in vivo.
NO20083605A 2006-03-28 2008-08-21 Stable oral pharmaceutical composition containing thyroid hormone receptor agonists NO20083605L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0606212.9A GB0606212D0 (en) 2006-03-28 2006-03-28 Pharmaceutical compositions
PCT/EP2007/002688 WO2007110226A1 (en) 2006-03-28 2007-03-27 Stable oral pharmaceutical composition containing thyroid hormone receptor agonists

Publications (1)

Publication Number Publication Date
NO20083605L true NO20083605L (no) 2008-11-07

Family

ID=36424743

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20083605A NO20083605L (no) 2006-03-28 2008-08-21 Stable oral pharmaceutical composition containing thyroid hormone receptor agonists

Country Status (20)

Country Link
US (1) US20090220598A1 (no)
EP (1) EP2004168B1 (no)
JP (1) JP2009531359A (no)
KR (1) KR20090013770A (no)
CN (1) CN101426488B (no)
AT (1) ATE518534T1 (no)
AU (1) AU2007229626A1 (no)
BR (1) BRPI0709688A2 (no)
CA (1) CA2642880A1 (no)
DK (1) DK2004168T3 (no)
ES (1) ES2369674T3 (no)
GB (1) GB0606212D0 (no)
MX (1) MX2008012385A (no)
NO (1) NO20083605L (no)
NZ (1) NZ570689A (no)
PL (1) PL2004168T3 (no)
PT (1) PT2004168E (no)
RU (1) RU2450810C2 (no)
WO (1) WO2007110226A1 (no)
ZA (1) ZA200807597B (no)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0724478D0 (en) * 2007-12-14 2008-01-30 Karobio Ab Pharmaceutical compositions
WO2012120053A1 (de) 2011-03-08 2012-09-13 Sanofi Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120052A1 (de) 2011-03-08 2012-09-13 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
US8710050B2 (en) 2011-03-08 2014-04-29 Sanofi Di and tri- substituted oxathiazine derivatives, method for the production, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
US8828994B2 (en) 2011-03-08 2014-09-09 Sanofi Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
EP2683700B1 (de) 2011-03-08 2015-02-18 Sanofi Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2609910A1 (en) 2011-12-30 2013-07-03 Deva Holding Anonim Sirketi Formulations of eprotirome
CN106727453B (zh) * 2017-01-13 2019-04-26 鲁东大学 一种化合物在制备治疗甲状腺机能减退症药物中的应用
CA3122996A1 (en) * 2018-12-12 2020-06-18 Autobahn Therapeutics, Inc. Novel thyromimetics
JP7503560B2 (ja) 2019-03-01 2024-06-20 オートバーン セラピューティクス，インク． 新規な甲状腺模倣物
IT201900006923A1 (it) * 2019-05-16 2020-11-16 International Soc For Drug Development S R L Nuovi tiromimetici con uno scaffold bifenilmetano e loro uso
CN115279359A (zh) * 2019-11-29 2022-11-01 速通医疗公司 新型拟甲状腺素药
US20230242471A1 (en) * 2020-06-17 2023-08-03 Autobahn Therapeutics, Inc. Thyromimetics
WO2024165571A2 (en) 2023-02-06 2024-08-15 E-Therapeutics Plc Inhibitors of expression and/or function
WO2025125576A2 (en) 2023-12-15 2025-06-19 E-Therapeutics Plc Inhibitors of expression and/or function
WO2025133348A1 (en) 2023-12-22 2025-06-26 E-Therapeutics Plc Inhibitors of expression and/or function

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5883294A (en) * 1997-06-18 1999-03-16 The Regeants Of The University Of California Selective thyroid hormone analogs
US5849337A (en) * 1997-06-27 1998-12-15 Gusty Winds Corporation Method of enhancing magnesium absorption and prevention of atherosclerosis
EP1257526B1 (en) * 2000-02-17 2005-05-11 Bristol-Myers Squibb Company Aniline-derived ligands for the thyroid receptor
AU2001211213A1 (en) * 2000-10-20 2002-04-29 Galephar M/F Stable oral formulation containing benzimidazole derivative
ITMI20011401A1 (it) * 2001-07-02 2003-01-02 Altergon Sa Formulazioni farmaceutiche per ormoni tiroidei
JP2005517720A (ja) * 2002-02-15 2005-06-16 キング・ファーマシューティカルズ・インコーポレイティッド レボチロキシン組成物及び方法
BR0310099A (pt) * 2002-05-17 2007-03-20 Esperion Therapeutics Inc método para tratar dislipidemia ou uma doença associada com a dislipidemia
GB0215978D0 (en) * 2002-07-10 2002-08-21 Karobio Ab Novel compounds
US20040028737A1 (en) * 2002-08-12 2004-02-12 Kopran Research Laboratories Limited Enteric coated stable oral pharmaceutical composition of acid unstable drug and process for preparing the same
TW200504021A (en) * 2003-01-24 2005-02-01 Bristol Myers Squibb Co Substituted anilide ligands for the thyroid receptor
US7670624B2 (en) * 2004-01-29 2010-03-02 Astella Pharma Inc. Gastrointestinal-specific multiple drug release system

Also Published As

Publication number Publication date
DK2004168T3 (da) 2011-10-31
CN101426488B (zh) 2012-03-21
WO2007110226A1 (en) 2007-10-04
EP2004168B1 (en) 2011-08-03
RU2450810C2 (ru) 2012-05-20
ATE518534T1 (de) 2011-08-15
MX2008012385A (es) 2009-03-02
HK1126404A1 (en) 2009-09-04
PL2004168T3 (pl) 2012-01-31
ES2369674T3 (es) 2011-12-02
EP2004168A1 (en) 2008-12-24
US20090220598A1 (en) 2009-09-03
AU2007229626A1 (en) 2007-10-04
KR20090013770A (ko) 2009-02-05
JP2009531359A (ja) 2009-09-03
RU2008142524A (ru) 2010-05-10
CN101426488A (zh) 2009-05-06
NZ570689A (en) 2011-12-22
BRPI0709688A2 (pt) 2011-07-19
GB0606212D0 (en) 2006-05-10
ZA200807597B (en) 2009-06-24
CA2642880A1 (en) 2007-10-04
PT2004168E (pt) 2011-10-24

Similar Documents

Publication Publication Date Title
NO20083605L (no) Stable oral pharmaceutical composition containing thyroid hormone receptor agonists
MX2009012000A (es) Derivados de pirazol heteroarilo sustituidos utiles para el tratamiento de trastornos hiperproliferativos y enfermedades asociadas a la angiogenesis.
SG171649A1 (en) Dpp iv inhibitor formulations
MY148634A (en) Pyridazinone derivatives
WO2009086400A3 (en) Recombinant vwf formulations
AU2009215514A9 (en) Composition comprising a combination of omeprazole and lansoprazole, and a buffering agent, and methods of using same
MX2009007337A (es) Indazoles sustituidos con 5-piridinona.
MX2010001754A (es) Derivados de azepina como inhibidores de gamma secretasa.
WO2010048275A3 (en) Lyophilized recombinant vwf formulations
UA98804C2 (ru) Катехоламиновые производные и фармацевтическая композиция на их основе
UA100007C2 (ru) Гетероциклические ингибиторы мек, их применение и фармацевтическая композиция, которая их содержит
NZ621174A (en) Powdered protein compositions and methods of making same
UA100227C2 (uk) Заміщені n-фенілметил-5-оксопролін-2-аміди як антагоністи p2x7-рецептора та їх застосування
MX2009004746A (es) Derivados de 1,2,4-triazol como inhibidores del receptor sigma.
CO6290655A2 (es) Inhibidors heterociclicos de estearoil-coa-desaturasa
BRPI0821128A2 (pt) Composição farmacêuticas
WO2009105969A8 (zh) 埃坡霉素类似物、其药物组合物、用途及其制备方法
SG158091A1 (en) Imidazoazepinone compounds
MX2010009848A (es) Composiciones para el suministro especifico en sitio de imatinib y metodos de uso.
TN2009000510A1 (en) Extended release formulation of nevirapine
MX2010004556A (es) Formulacion farmaceutica de acido clavulanico.
NO20081721L (no) Stabil fast formulering av sertindol
MX2009012370A (es) Formulacion de antraciclina de baja viscosidad.
MY157425A (en) Substituted oxindole derivatives and the use thereof for the treatment of vasopressin-dependent illnesses
MX2010006215A (es) Derivados de piperazina y su uso como moduladores del receptor de leptina.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application